There are 3162 resources available
Introduction and scientific background
Presenter: Leslie Ballas
Session: Can we expand bladder preservation by optimal use of systemic therapy and biomarkers?
Resources:
Slides
Webcast
Introduction and scientific background
Presenter: Pan-Chyr Yang
Session: Lung cancer interception: New approaches to lung cancer screening and prevention
Resources:
Slides
Webcast
Introduction and scientific background
Presenter: Amanda Psyrri
Session: Personalised immunotherapy strategies for head and neck cancers
Resources:
Webcast
Risk of gonadal toxicities with anticancer therapies with a focus on newer treatments
Presenter: Isabelle Demeestere
Session: Oncofertility: What every HCP involved in cancer care should know
Resources:
Slides
Webcast
Introduction
Presenter: Jayne Wood
Session: 9th ESMO Designated Centres of Integrated Oncology and Palliative Care session and awards: Specific considerations for integration of oncology and palliative care
Resources:
Slides
Webcast
Introduction
Session: ESMO Virtual Plenary revisited
Resources:
Webcast
LBA38 - Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC): A randomized, open-label, phase II/III study (DUBHE-H-308)
Presenter: Shukui Qin
Session: Proffered paper session 1: GI tumours, upper digestive
Resources:
Abstract
Slides
Webcast
988O - A phase I/II trial (LOKON003) evaluating tumor microenvironment (TME) gene engineering using a viral vector combined with atezolizumab in advanced malignant melanoma
Presenter: Gustav Ullenhag
Session: Proffered paper session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
603O - First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation
Presenter: Robin Guo
Session: Proffered paper session 1: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
1925MO - Regomune study: A phase II study of regorafenib + avelumab in solid tumors. Results of the radioiodine-refractory differentiated thyroid cancer (RR-DTC)
Presenter: Sophie Cousin
Session: Mini oral session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast